Keyword: Amgen

News

Amgen Ends Non-U.S. Co-Marketing Pact With GSK

11.04.2014 - U.S. biotechnology firm Amgen, the world's largest, is ending its agreement with the U.K. drugmaker GlaxoSmithkline for the marketing of its osteoporosis drug in some regions...

News

Catalent Announces Two Senior Appointments to Expand Biologics Business

11.03.2014 - Catalent Pharma Solutions announced two senior appointments to further strengthen its global biologics business. Andrew Sandford joins Catalent as Vice President Business...

News

The Biosimilar Market

07.02.2014 - Pharmaceuticals - Many biologic drug developers can be pleased with how well their products have performed in the market place. Blockbuster products such as Abbvie's (ex-Abbott)...

News

Amgen Buys Onyx for $10.4 Billion

26.08.2013 - Amgen struck a deal to buy cancer drug maker Onyx Pharmaceuticals for about $10.4 billion on Sunday, as it moves to restock its product pipeline in response to declining sales of...

News

Onyx Provides Drug Trial Data to Amgen, Other Potential Bidders

23.08.2013 - Onyx Pharmaceuticals has given potential buyers, including Amgen, access to trial data on its new cancer drug, removing a key hurdle that was holding up deal talks, according to...

News

Amgen deal for Onyx possible Within Week

09.08.2013 - Onyx Pharmaceuticals is close to selling itself to larger rival Amgen as the cancer drug maker's high stock price has discouraged other companies from making a counteroffer so far...

News

Alexion Valuation Could Choke Any Roche Bid

15.07.2013 - Buying Alexion Pharmaceuticals would help Roche make a splash in the newly lucrative area of rare or so-called orphan diseases, but it could command a price that the Swiss...

News

Sanovel Up For Sale

03.07.2013 - Turkish generic drug maker Sanovel has been put up for sale by parent Toksoz Holding and could fetch between $500 million and $1 billion, three sources close to the matter told...